12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral salmon calcitonin: Development discontinued

Emisphere said partner Novartis discontinued development of SMC021 to treat postmenopausal osteoporosis and OA. Emisphere said the pharma's decision was based on data from the Phase III Study 2303 trial in postmenopausal osteoporosis and the Phase III Study 2301 and 2302 trials in OA. Novartis' development partner Nordic Bioscience...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >